1. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2013;31:105-114.
3. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012;62:63-77.
7. Kavalali ET, Monteggia LM. How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol 2015;20:35-39.
8. Sild M, Ruthazer ES, Booij L. Major depressive disorder and anxiety disorders from the glial perspective: Etiological mechanisms, intervention and monitoring. Neurosci Biobehav Rev 2017;83:474-488.
9. Wang Q, Jie W, Liu JH, Yang JM, Gao TM. An astroglial basis of major depressive disorder? An overview. Glia 2017;65:1227-1250.
11. Zhang F, Zhang C. Rnf112 deletion protects brain against intracerebral hemorrhage [ICH] in mice by inhibiting TLR-4/NF-κB pathway. Biochem Biophys Res Commun 2018;507:43-50.
12. Bhattacharya A, Jones DNC. Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders. Psychoneuroendocrinology 2018;98:95-100.
13. Alyu F, Dikmen M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. Acta Neuropsychiatr 2017;29:1-16.
15. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992;16:525-534.
16. Sarkisova KY, Kuznetsova GD, Kulikov MA, van Luijtelaar G. Spikewave discharges are necessary for the expression of behavioral depression-like symptoms. Epilepsia 2010;51:146-160.
20. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Stertz L, Kapczinski F, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:450-455.
27. Kim KN, Ko SC, Ye BR, Kim MS, Kim J, Ko EY, et al. 5-Bromo-2-hydroxy- 4-methyl-benzaldehyde inhibited LPS-induced production of pro-inflammatory mediators through the inactivation of ERK, p38, and NF-κB pathways in RAW 264.7 macrophages. Chem Biol Interact 2016;258:108-114.
28. Wu Y, Li W, Zhou C, Lu F, Gao T, Liu Y, et al. Ketamine inhibits lipopolysaccharide- induced astrocytes activation by suppressing TLR4/NF-ĸB pathway. Cell Physiol Biochem 2012;30:609-617.
29. Welters ID, Hafer G, Menzebach A, Mühling J, Neuhäuser C, Browning P, et al. Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. Anesth Analg 2010;110:934-941.
30. Yu M, Shao D, Yang J, Feng S, Xu J. Ketamine suppresses intestinal TLR4 expression and NF-kappaB activity in lipopolysaccharide-treated rats. Croat Med J 2006;47:825-831.
32. Yu M, Shao D, Liu J, Zhu J, Zhang Z, Xu J. Effects of ketamine on levels of cytokines, NF-kappaB and TLRs in rat intestine during CLP-induced sepsis. Int Immunopharmacol 2007;7:1076-1082.
35. Liu W, Wang Y, Li H, Ji L. The role of nitric oxide in the antidepressant actions of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside in insulin-resistant mice. Psychosom Med 2016;78:102-112.
38. Chen RM, Chen TL, Lin YL, Chen TG, Tai YT. Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells by down-regulating endothelial nitric oxide synthase expression and intracellular calcium levels. Crit Care Med 2005;33:1044-1049.
39. Weckmann K, Deery MJ, Howard JA, Feret R, Asara JM, Dethloff F, et al. Ketamine’s Effects on the Glutamatergic and GABAergic Systems: A Proteomics and Metabolomics Study in Mice. Mol Neuropsychiatry 2019;5:42-51.
40. Tan S, Wang Y, Chen K, Long Z, Zou J. Ketamine alleviates depressivelike behaviors via down-regulating inflammatory cytokines induced by chronic restraint stress in mice. Biol Pharm Bull 2017;40:1260-1267.
41. Taniguchi T, Shibata K, Yamamoto K. Ketamine inhibits endotoxininduced shock in rats. Anesthesiology 2001;95:928-932.
42. Helmer KS, Cui Y, Chang L, Dewan A, Mercer DW. Effects of ketamine/xylazine on expression of tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclo-oxygenase-2 in rat gastric mucosa during endotoxemia. Shock 2003;20:63-69.
45. Zhu X, Li P, Hao X, Wei K, Min S, Luo J, Xie F, Jin J. Ketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of neuroinflammation and soluble amyloid-beta peptide in depressive-like rats. Neurosci Lett 2015;599:32-37.
46. Fehlings MG, Nguyen DH. Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury. J Clin Immunol 2010;30(Suppl 1):S109-S112.
47. Zhang GF, Liu WX, Qiu LL, Guo J, Wang XM, Sun HL, et al. Repeated ketamine administration redeems the time lag for citalopram’s antidepressant- like effects. Eur Psychiatry 2015;30:504-510.